Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14982195 | 0.84 | KMT2A (0.52) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL18844093 | 0.79 | MEN1 (0.68) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| Dibenzoylmethane SCHEMBL28291887 | 0.76 | MEN1 (0.94) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL27398577 | 0.75 | NOS3 (0.39) | MAPTSMN1; SMN2HPGDKDM4ETDP1 | |
| SCHEMBL4327538 | 0.74 | HIF1A (0.56) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL14982175 | 0.74 | NPC1 (0.64) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL14982178 | 0.74 | MEN1 (0.55) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| Dibenzoylmethane SCHEMBL39582 | 0.74 | MEN1 (1.00) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| Dibenzoylmethane SCHEMBL1704711 | 0.74 | MEN1 (1.00) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 | |
| Dibenzoylmethane SCHEMBL10356288 | 0.74 | MEN1 (1.00) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785696-B1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8822464-B2 | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822464-B2 | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8741892-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013079460-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20130137688-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137688-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137688-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | MEN1 4795/4885KMT2A 1443/4885MAPT 281/4885 |
| US-20130143870-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | MEN1 4793/4885KMT2A 1800/4885MAPT 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.